Written consent was obtained from treating physicians to communicate with and examine the patients for further data collection.
Follow-up data regarding attainment of remission, relapse, requirement for second-line and subsequent therapy, date of death and cause of death were obtained from treating physicians or case-note review.
The highest flexural, tensile and impact strength were obtained from treated kenaf with 15/15 v/v KG fibres reinforced UPE hybrid composite in this investigation.
Soluble fraction, or nuclear fractions, or conditioned medium was obtained from treated cells and we analyzed the genes identified as differentially expressed in the microarray (when antibodies were available) as well as some genes known to be regulated by Wnt, such as E-cadherin, β-catenin or cyclin D. Our data confirmed some of the variations in the genes described.
Spinal cord sections were obtained from treated animals at end stage.
Protein samples were obtained from treated and nontreated cells using RIPA lysing buffer.
However, at all subsequent timepoints, ranging from 1 to 5 weeks, comparable numbers of CFU-initiating cells were obtained from treated and untreated BMC cultures.
Animals were then sedated and sacrificed, and glandular tissue samples were obtained from treated udders at 2, 4, 6 and 8 cm height.
Three GI sequences were identical (strains 16, 24, and 42), 2 of which were obtained from treated wastewater 3 months apart (strains 24 and 42), and 1 was obtained from the river water (strain 16).
The PBMCs that were obtained from treated patients 4 7 days after CTX administration (B1, Fig. 2a) displayed a slight although statistically significant decrease in the frequency of activated CD4+CD25hiFoxp3+ Tregs compared with the pre-treatment samples (B0, Fig. 2a) (% of Tregs mean ± SEM: B0 (1.7 ± 0.3), B1 (1.3 ± 0.2); p = 0.0215).
